Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer's disease - PubMed
6 hours ago
- #Alzheimer's disease
- #network meta-analysis
- #cognitive outcomes
- Network meta-analysis compared nine Alzheimer's drugs (aducanumab, lecanemab, donanemab, gosuranemab, semorinemab, tilavonemab, zagotenemab, masupirdine, sodium oligomannate) against placebo for cognitive outcomes.
- No drug showed statistically significant superiority over placebo on primary outcomes (CDR-SB and ADAS-cog), based on 15 randomized trials with 33 treatment arms.
- Tau-targeted antibodies semorinemab and tilavonemab ranked highest in SUCRA analysis but lacked significant pairwise advantages.
- Aducanumab had a modest mean difference on MMSE (1.98, 95% CI 0.03-3.93) versus placebo, though publication bias reduces confidence in this finding.
- Conclusions indicate current pharmacological treatments do not consistently outperform placebo; more rigorous trials and improved preclinical models are needed.